GlassScriptPhysician profile
Hannah Claire Wangberg
NPI 1306233663
$8,938.55
in general payments reported to CMS, 2019-2025
33 companies · $2,840 in 2025
The $2,840 reported for 2025 was more than what 75% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.95 · 2020: $178 · 2021: $846 · 2022: $1,183 · 2023: $2,143 · 2024: $1,719 · 2025: $2,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,576 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,575.77 |
| Education | $125.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,788.36 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,525.83 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $810.51 | 2020-2025 | Takhzyro, Cuvitru, Entyvio |
| Regeneron Healthcare Solutions, INC. | $575.74 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $512.56 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Leo Pharma INC. | $396.68 | 2024-2025 | Adbry |
| Grifols USA, LLC | $335.32 | 2022-2025 | Xembify, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $334.92 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.37 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Alk-Abello, INC | $226.05 | 2021-2025 | Ragwitek, Odactra, Grastek |
| Ars Pharmaceuticals Operations, INC. | $218.93 | 2025 | Neffy |
| Csl Behring | $195.91 | 2021-2024 | Hizentra |
| Pfizer INC. | $188.05 | 2021-2025 | |
| Amgen INC. | $173.53 | 2022-2025 | Tezspire, Actimmune |
| Sanofi-Aventis U.S. LLC | $170.99 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $147.57 | 2019-2024 | Auvi-Q |
| Pharming Healthcare, INC. | $142.41 | 2021-2024 | Ruconest |
| Biocryst US Sales Co., LLC | $128.88 | 2021-2025 | Orladeyo |
| Genentech USA, INC. | $127.34 | 2022-2025 | Xolair |
| Blueprint Medicines Corporation | $125.77 | 2024-2025 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $91.97 | 2025 | Dawnzera |
| Incyte Corporation | $88.75 | 2022-2025 | Opzelura |
| Abbvie INC. | $67.16 | 2025 | |
| Lilly USA, LLC | $66.71 | 2024-2025 | Ebglyss, Omvoh, Zepbound |
| Janssen Biotech, INC. | $44.37 | 2024-2025 | Stelara, Simponi, Tremfya |
| Optinose US, INC. | $40.37 | 2025 | |
| Siemens Medical Solutions USA, INC. | $29.76 | 2025 | Immulite 1000 Immunoassay System |
| Hospira, INC. | $23.89 | 2023 | |
| Arcutis Biotherapeutics, INC. | $22.08 | 2025 | Zoryve |
| Bio Products Laboratory USA, INC. | $17.54 | 2023 | Gammaplex, Coagadex |
| Braintree Laboratories, INC. | $16.89 | 2023 | Sutab |
| Celltrion USA INC. | $16.37 | 2025 | Vegzelma |
| Galderma Laboratories, L.P. | $13.97 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Wangberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.